Curated News
By: NewsRamp Editorial Staff
October 29, 2026
Annovis Bio CEO to Present at Two November Biotech Conferences
TLDR
- Annovis Bio CEO Maria Maccecchini will pitch buntanetap's Phase 3 Alzheimer's and Parkinson's progress to partners at two November conferences, opening deal opportunities.
- Buntanetap is a once-daily oral drug that inhibits translation of neurotoxic proteins like APP, tau, and alpha-synuclein through an RNA-targeting mechanism.
- Annovis Bio's buntanetap aims to halt neurodegeneration and improve cognitive and motor function for Alzheimer's and Parkinson's patients worldwide.
- Annovis Bio CEO Maria Maccecchini will speak on bridging the translational gap at U.S. Biotech Day 2026 and present buntanetap data in Boston.
Impact - Why it Matters
The presentations at U.S. Biotech Day and Pharma Partnering Summit offer Annovis Bio a valuable platform to showcase its clinical progress and the potential of buntanetap to a targeted audience of industry stakeholders, investors, and potential partners. As a Phase 3-stage company, these engagements could enhance visibility, attract strategic partnerships, and ultimately accelerate the development of much-needed therapies for Alzheimer’s and Parkinson’s diseases, which affect millions worldwide. The one-on-one meetings may also lead to collaborations that provide additional resources to advance buntanetap through clinical trials, bringing hope to patients and families awaiting new treatment options.
Summary
Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company focused on neurodegenerative diseases, has announced that its Founder, President and CEO Maria Maccecchini, Ph.D., will participate in two prominent industry conferences in November 2026. At U.S. Biotech Day 2026, taking place November 16-17 in Philadelphia, Maccecchini will join a panel discussion titled “Bridging the Translational Gap: From Discovery Insights to Clinical Proof” on November 16 from 9:15-9:45 a.m. ET, followed by a company presentation from 10:15-10:30 a.m. ET that will highlight Annovis’ clinical programs and upcoming milestones. She will also hold one-on-one meetings with biotechnology and pharmaceutical representatives to discuss the company’s progress and potential opportunities.
Later that week, Maccecchini will present at the Pharma Partnering Summit 2026, scheduled for November 19-20 in Boston. Her presentation, titled “Restoring Proteostasis in Alzheimer’s and Parkinson’s Diseases with Buntanetap, a Translational Inhibitor of Neurotoxic Proteins,” will take place on November 19 from 11:25-11:55 a.m. ET. The summit provides another platform for Maccecchini to engage in one-on-one meetings with industry representatives, further discussing Annovis’ clinical advancements and strategic partnerships.
Annovis Bio, headquartered in Malvern, Pennsylvania, is developing its lead drug candidate buntanetap (formerly posiphen), an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions in patients with Alzheimer’s and Parkinson’s. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Annovis Bio CEO to Present at Two November Biotech Conferences
